read carefully-limited sales 05, page-2

Hi yavanna,

This article allows some extrapilation...

Given that GSK has throughout 2005 NOT increased its production capacity and only delivered UK#4m from its existing production facilities, we can work out that they produced approx 320,000 courses of Relenza

UK# x FX divided by A$cost per course
4m x 2.4 / 30 = 320,000 courses

Now, consider that GSK has substantially increased production capabilities and has multiply sites around the world producing Relenza to fill the official orders that we know about (i.e. Germany, France, Australia, Hong Kong, Netherlands) which amounts to, at least, 15m courses of Relenza.

Now, lets do the maths (in light of the comments by the GSK spokesperson who said ""Looking at the orders we have had for Relenza towards the end of last year, we expect to see a significant increase in sales in 2006")...

Courses x A$30 / UK# = GSK Revenue (UK)

15m x 30 / 2.4 = 187,500,000

So UK# sales increases significantly from UK4m to UK187m in 2006.

Now, bring on the US order, the WHO order, the rest of the world and the orders from Govt (e.g. UK) who have previously stockpiled only Tamiflu!!!!!